Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Fiore

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survivalPaul L Nguyen, Jing Ma, Jorge E Chavarro, et al.
Journal of the National Cancer Institute|March 26, 2009
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancerToshiro Migita, Stacey Ruiz, Alessandro Fornari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
SPINK1 protein expression and prostate cancer progressionRichard Flavin, Andreas Pettersson, Whitney K Hendrickson, et al.
Developmental Cell|December 20, 2022
ΔNp63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cellsArthur W Lambert, Christopher Fiore, Yogesh Chutake, et al.
Science Translational Medicine|March 22, 2019
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapyMarie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, et al.
Cell|July 28, 2009
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancerQianben Wang, Wei Li, Yong Zhang, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survivalPaul L Nguyen, Jing Ma, Jorge E Chavarro, et al.
Journal of the National Cancer Institute|March 26, 2009
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancerToshiro Migita, Stacey Ruiz, Alessandro Fornari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
SPINK1 protein expression and prostate cancer progressionRichard Flavin, Andreas Pettersson, Whitney K Hendrickson, et al.
Developmental Cell|December 20, 2022
ΔNp63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cellsArthur W Lambert, Christopher Fiore, Yogesh Chutake, et al.
Science Translational Medicine|March 22, 2019
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapyMarie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, et al.
Cell|July 28, 2009
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancerQianben Wang, Wei Li, Yong Zhang, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Pageof 2